Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer
September 18, 2018 07:30 ET
|
Deciphera Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
Deciphera Pharmaceuticals, Inc. Added to Russell 2000® Index
December 18, 2017 07:00 ET
|
Deciphera Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
Deciphera Pharmaceuticals, Inc. Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors
November 28, 2017 07:00 ET
|
Deciphera Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 21, 2017 07:00 ET
|
Deciphera Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
November 20, 2017 07:00 ET
|
Deciphera Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights
November 14, 2017 07:00 ET
|
Deciphera Pharmaceuticals, Inc.
-Presented Updated Clinical Data from Ongoing Phase 1 Trial of DCC-2618 at ESMO- -Completion of Initial Public Offering Raising Net Proceeds of $129 million- -Announced Plans to Initiate Two...
Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society
November 10, 2017 07:00 ET
|
Deciphera Pharmaceuticals, Inc.
- Data Support the Selection of the Recommended Daily Dose of 150 mg - - Durable Disease Control Rates in Heavily Pretreated GIST Patients and Reductions in KIT Mutations Supporting pan-KIT Activity...
Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
November 06, 2017 08:17 ET
|
Deciphera Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
Deciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares
October 03, 2017 07:30 ET
|
Deciphera Pharmaceuticals LLC
WALTHAM, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering
September 27, 2017 21:49 ET
|
Deciphera Pharmaceuticals LLC
WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...